PO-0977: BED is not a significant factor for biological recurrence after prostate brachytherapy in Japanese patients  by Miki, K. et al.
S374  2nd ESTRO Forum 2013 
PO-0977   
BED is not a significant factor for biological recurrence after 
prostate brachytherapy in Japanese patients 
K. Miki1, M. Kido1, M. Aoki2, T. Kimura1, C. Kanehira2, S. Egawa1 
1Jikei University School of Medicine, Department of Urology, Minato-
ku, Japan  
2Jikei University School of Medicine, Department of Radiation 
Oncology, Minato-ku, Japan  
 
Purpose/Objective: To analyze long-term outcome for Biochemical 
recurrence (BCR) after prostate brachytherapy (PPB) in Japanese 
patients. 
Materials and Methods: Between October 2003 and March 2010, 604 
consecutive patients with clinically localized prostate cancer (PCa) 
were treated with PPB in Jikei University Hospital. Median follow-up 
was 48 months. Among 604 patients, 260 patients (43%) were treated 
with neoadjuvant, 45 (7.6%) were treated with adjuvant hormone 
therapy (HT) and 75 (12.4%) were treated with supplemental external 
radiation therapy (EBRT). BCR was defined as nadir PSA +2ng/ml, 
using the Phoenix definition. Toxicity was reported according to 
CTCAE v4.0. 
Results: Of the 604 patients, 219 (34.6%) were low-risk, 361(59.8%) 
were intermediate-risk and 24 (4.0%) were high-risk. The median BED 
for all patients was 174.4Gy2. At 8 years, BCR-free survival, cancer 
specific survival and overall survival was 82.2%, 100% and 95.6%, 
respectively. BCR-free survival at 8 years was 89.9%, 79.4%and 52.5%, 
for low-, intermediate-, and high-risk group, respectively. BCR-
freesurvival of high-risk group was significantly lower than that of 
low- and intermediate-risk group (p<0.001). BCR-free survival by BED 
dose was not significantly different. In the multivariate analysis, 
younger age (p=0.045), higher PSA (p=0.004), higher Gleason score 
(p=0.006), higher clinical T stage (0.008), disuse of HT(p=0.0021) and 
disuse of EBRT (p=0.010) were significant variables associated with 
BCR. Only 3 patients had G3 genitourinary or gastrointestinal toxicity. 
Conclusions: PPB results in excellent oncological outcome and 
tolerable toxicity in Japanese patients. BED was not a significant 
predictive factor for BCR in this cohort.  
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Purpose/Objective: Retrospectively to analyze short and 
intermediate-term outcomes and toxicity after salvage BT with I125 
for local failure after BT or EBRT for prostate cancer. 
Materials and Methods: Between January´10 and September´12, 16 
patients with PSA relapse (Phoenix definition for those with previous 
AD and ASTRO definition for the rest), after histological confirmation 
with template-guided biopsy, underwent salvage BT with I125 at least 
2 years ago from initial treatment (8 BT and 8 EBRT). At relapse, 
average age was 71 years-old (58-82), median Gleason was 7 (not 
determinated-9) and PSA pre-salvage BT 5.65 ng/ml (2.81-11.7). Two 
patients were treated with AD previously salvage BT. The median dose 
to 90% of prostate volume was 129.1 Gy (84.18-151.47) with a median 
seed activity of 0.506 mCi (0.319-0.518). Constraint doses for urethra 
and rectum were 162 Gy and 120 Gy respectively. Toxicities were 
graded using CTCv4.0. 
Results: With a median follow up was 13.5 months (2-32), 11 (68%) 
patients are freedom from biochemical failure. 5 patients have 
developed PSA relapse (2 with distant failure evidence and 2 within 
the first 6 months). There were one Grade 3 toxicity (TURP after 
acute urine retention) and two Grade 2 toxicities (acute rectal 
mucositis and acute cystitis in the same patient). 
Conclusions: Despite of the short follow-up in some patients, BT is a 
safe and effective treatment option for salvage treatment, but careful 
patient selection is essential to improve outcomes. 
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Purpose/Objective: The optimal protocol for low dose rate 
brachytherapy (LDR) in intermediate-risk prostate cancer patients 
remains controversial. We evaluated our retrospective, single 
institution experience LDR with short term androgen deprivation 
therapy(sADT) (protocol-Intermediate risk group: Protocol IRG). 
Materials and Methods: From April 2005 to November 2012, 440 
patients underwent PPB with I-125. We assessed consecutive 285 
patients, treated with LDR without supplemental external beam 
radiation therapy, including low risk patients (LRG); 147 patients and 
Protocol-IRG; 139 patients. Prostate specific antigen (PSA) failure was 
defined as nadir plus 2 ng/m, and benign PSA bounce was also 
assessed in men with PSA failure. For the evaluation of treatment-
related morbidity, we used CTCAE ver.4. 
Results: Median follow up length (Protocol IRG vs. LRG) was53 months 
vs. 55 months, respectively. Pretreatment PSA value was 9.4 ± 4.4 
vs6.4 ± 1.6 (p< 0.05). For Protocol IRG and LRG patients, actuarial 5-
year overall survival; 97.6% vs. 99.2%; causespecific survival, 100%vs. 
100%; distant metastasis-free survival were 100%vs.100%; 5-year bNED 
(not including PSA bounce) was 99.3% vs. 100%. Acute GU toxicity 
above grade 2 was seen in 2% ofpatients (1% vs. 1%). Late GU toxicity 
above grade 3 was seen in 1 patient (LRGpatient) who underwent 
TURP. Late GI toxicity of grade 2 with rectal hemorrhageoccurred in 
1.4% (0.7% vs. 0.7%), which were successfully treated by 
steroidenema. 
Conclusions: Protocol IRG might be a good protocol for intermediate-
risk patients which demonstrates good outcome and less morbidity as 
for low risk patients.  
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Purpose/Objective: Several investigations have revealed that the 
alpha/beta ratio for prostate cancer is atypically low, and that 
hypofractionated radiotherapy or high-dose-rate brachytherapy (HDR-
BT) regimens using appropriate radiation doses are expected to 
improve the local control rate for localized prostate cancer. However, 
the increase in the total biological effective dose (BED) may cause an 
increase in the severity and incidence of normal tissue complications. 
The purpose of this study was to investigate if the clinical and 
dosimetric factors affected the incidence of rectal toxicity after HDR-
BT combined with external beam radiotherapy (EBRT). 
Materials and Methods: The records of 186 patients with localized 
prostate cancer treated by HDR-BT combined with EBRT between 
November 2004 and December 2010 were analyzed. The fractionation 
schema for HDR-BT and EBRT was prospectively changed. The 
distribution of the fractionation schema used in the patients was as 
follows: 9 Gy x 2 + 2 Gy x 20 (BED1.5 = 219 Gy, BED3 = 139 Gy) in 
57patients (Group 1); and 9 Gy x 2 + 3 Gy x 13 (BED1.5 = 243 Gy, BED3= 
150 Gy) in 129 patients (Group 2). The median follow-up duration was 
54 months (range 23 – 96 months). The toxicities were graded based 
on the National Cancer Institute-Common Terminology Criteria for 
Adverse Events v3.0. The clinical and dosimetric factors affecting the 
incidence of Grade 2 or worse late rectal toxicity were analyzed by 
statistical analyses. 
Results: Twenty (10.8%) and one patients developed Grade 2 rectal 
bleeding and Grade 3 rectal ulcer, respectively. There were no 
significant differences between Group 1 and Group 2 in the incidence 
of rectal toxicity (12.3% and 10.9%, respectively). There was no 
statistically-significant correlation between the incidence of Grade 2 
and 3 rectal toxicity and BED escalation. Grade 2 and 3 rectal toxicity 
occurred in 7 out of 36 (19.4 %) patients receiving the antiplatelet 
therapy, while it occurred in 14 out of 141 (9.9%) patients without a 
history of antiplatelet therapy, and Grade 2 and 3 rectal toxicity 
occurred much more in the patients receiving the antiplatelet therapy 
than those without a history of antiplatelet therapy, however it was 
no statistically-significant difference between two groups in 
univariate analysis. Grade 2 and 3 rectal toxicity occurred in 3 out of 
9 (33.3 %) patients with DM, while it occurred in 18 out of 177 
(10.2%)patients without DM, and Grade 2 and 3 rectal toxicity 
occurred much more in the patients with DM than those without DM, 
however it was also no statistically-significant difference between two 
groups in univariate analysis. Regarding the correlation with 
dosimetric factors, there were significant differences between those 
with and without rectal toxicity in V70, V75, D2cc, and D1cc in HDR-
BT in univariate analysis. Especially, V70 > 3.5cc, V75 > 2cc, D2cc> 7 
Gy, and D1cc > 7.4 Gy were statistically-significant risk factors. 
Conclusions: BED escalation could be performed without severe rectal 
toxicity in HDR-BT combined with EBRT. V75 >2cc, V90 > 0.2cc, D2cc > 
7 Gy, D1cc > 7.4 Gy were risk factors for the incidence of rectal 
toxicity in HDR-BT combined with EBRT. 
